Hyperreflective foci on optical coherence tomography associate with treatment outcome for anti-VEGF in patients with diabetic macular edema by Schreur, V. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
RESEARCH ARTICLE
Hyperreflective foci on optical coherence
tomography associate with treatment
outcome for anti-VEGF in patients with
diabetic macular edema
Vivian SchreurID1, Lebriz Altay2, Freekje van Asten1, Joannes M. M. Groenewoud3,
Sascha Fauser2, B. Jeroen Klevering1, Carel B. Hoyng1, Eiko K. de Jong1*
1 Department of Ophthalmology, Donders Institute for Brain, Cognition and Behaviour, Radboud University
Medical Center, Nijmegen, The Netherlands, 2 Department of Ophthalmology, University Hospital of





To investigate the relationship between baseline number of hyperreflective foci (HF) on
spectral domain optical coherence tomography (SD-OCT) in patients with diabetic macular
edema (DME), as well as the dynamics of HF during treatment with anti-vascular endothelial
growth factor (VEGF), and treatment response.
Methods
We evaluated patients diagnosed with DME scheduled for treatment with intravitreal bevaci-
zumab. Eyes were classified as adequate or insufficient treatment responders based on log-
MAR visual acuity improvement and central retinal thickness (CRT) decrease after three
consecutive injections. Associations between number of HF at baseline and treatment
response, the change in HF over the course of treatment, and the distribution of HF within
the retinal layers were evaluated.
Results
In 54 eyes of 41 patients, mean number of HF and CRT decreased after intravitreal treat-
ment with bevacizumab (p = 0.002 and p<0.001 respectively). Decrease in CRT after 3
months was independently associated with a higher number of HF at baseline (estimated
effect -2.61, 95% CI [-4.42–-0.31], p = 0.006). Eyes with adequate treatment response pre-
sented with more HF at baseline (OR 1.106, 95% CI [1.012–1.210], p = 0.030) than eyes
with insufficient treatment response. Most HF were located within the inner retinal layers,
and decrease of HF was mostly due to a decrease of inner retinal HF.
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Conclusions
In patients with DME treated with anti-VEGF, higher baseline numbers of HF have predictive
value for treatment response in terms of visual acuity improvement and CRT decrease after
3 months. In addition, HF were responsive to anti-VEGF therapy.
Introduction
Diabetic macular edema (DME) is a sight threatening complication of diabetes mellitus (DM)
and one of the most frequent causes of vision loss.[1] Because vascular endothelial growth fac-
tor (VEGF) plays a central role in the development of centre-involved DME, anti-VEGF agents
have been implemented as the treatment of choice for this condition. However, not all patients
respond equally well to the initiated treatment, in which case patients are redirected to treat-
ment with an alternative anti-VEGF agent or long acting corticosteroids.[2] Currently, we are
not able to choose the best treatment option for an individual patient a priori, because infor-
mation on baseline characteristics that associate with treatment outcomes is lacking. Any
delay in finding the most effective personalized treatment strategy may result in irreversible
visual impairment and also increases the costs of health care.[3]
Although visual function is the most relevant outcome measure, it is a subjective measure
of treatment response, and can be influenced by for example fluctuations in glucose levels or
the presence of other ocular disorders. Conversely, anatomical measurements such as central
retinal thickness (CRT) on spectral domain optical coherence tomography (SD-OCT) are a
more objective and reliable outcome measure for treatment response. The diabetic retinopathy
clinical research network (DRCR.net) employs a combination of both outcome measures and
defined insufficient treatment response as a CRT decrease of�10%, or a gain of�5 letters on
the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart, the equivalent of 0.1 log-
MAR.[4, 5]
Hyperreflective foci (HF) are well-circumscribed dots that can be visualized on SD-OCT in
all retinal layers. They were first described in patients with DM by Bolz et al. and have since
been associated with the presence of DME, as well as with non-proliferative stages of diabetic
retinopathy.[6, 7] Hypotheses about their etiology diverge: some authors suggested they could
be lipid extravasations acting as subclinical hard exudates.[6, 8, 9] Others have argued that HF
are migrating RPE cells since the reflectivity of HF corresponds with that of the RPE,[10] or
that they might be degenerated photoreceptor cells.[11] Another theory is that HF are aggre-
gates of cells involved in retinal inflammatory response, such as activated microglia.[12]
The purpose of this study was to investigate the association between baseline number of HF
and treatment response to anti-VEGF in terms of visual acuity (VA) improvement and CRT




We reviewed the medical files of DM type 2 patients with DME who were treated with intravi-
treal injections of bevacizumab (1.25 mg) at the department of Ophthalmology of the Radboud
University Medical Center between November 2010 and May 2013. We restricted inclusion to
treatment naive patients who received a complete loading dose of three consecutive injections
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with a 4–6 weeks interval, and of whom baseline and 3 month follow up data were available.
Other exclusion criteria were: laser treatment or intraocular surgery within 12 weeks prior to
the first injection, active proliferative diabetic retinopathy, vitreous hemorrhage or tractional
retinal detachment at baseline visit, and presence of other retinal vascular diseases. This study
adhered to the tenets of Helsinki. The Research Ethics Committee of the Radboud university
medical center Nijmegen approved this study and waived the requirement for informed con-
sent (2018–4424). All data was fully anonymized before it was accessed by the investigators.
Data collection
The following clinical characteristics were assessed: gender, age, duration of DME, and DR
staging according to International Clinical Diabetic Retinopathy Severity Scale.[13] At baseline
and 3 month visits, Snellen VA was measured and converted to the logarithm of the maximum
angle of resolution (logMAR). We used SD-OCT-scans (Spectralis HRA+OCT, Heidelberg
Engineering, Heidelberg, Germany) to automatically measure CRT as the average thickness in
an area of 1000 μm diameter surrounding the foveal centre. Adequate response was defined as
a CRT decrease of>10% and a VA improvement of>0.1 logMAR.[4, 5]
Image grading
We selected baseline and 3 months B-scans centered on the fovea and evaluated these scans for
the presence of HF within the central 3000 μm around the fovea (Fig 1). HF were defined as
small, round or oval-shaped, well-circumscribed dense particles with higher reflectivity than
the background. The size could not exceed 100 μm, as we hypothesized this to be clumps that
can be visualized as hard exudates on fundus photographs. The total number of HF in each
scan was counted, as well as the number of foci within the inner (inner nuclear layer) and
outer (outer plexiform layer to outer border of the external limiting membrane) retinal layers.
Fig 1. Hyperreflective foci on SD-OCT before and after treatment with anti-VEGF. Foveal centered spectral
domain optical coherence tomography (SD-OCT) B-scan image of a patient with DME before (A) and after (B) 3
injections with anti-VEGF. Black arrows indicate hyperreflective foci, within 3000 μm of the fovea (dashed bars).
https://doi.org/10.1371/journal.pone.0206482.g001
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The nerve fiber layer through the inner plexiform layer, and the photoreceptor layer and the
retinal pigment epithelium (RPE) were excluded from analysis, because the naturally high
reflectivity of these layers impedes the evaluation of HF. Additionally, the number of HF with
a higher reflectivity than the RPE were counted. Grading was performed by two experienced
independent graders (LA, VS), masked to all clinical information. In case of disagreement in
counted number of HF between the two graders exceeded 20%, differences were resolved
through discussion. For all other observations, the average of both graders was used for analy-
sis. In addition, the observers graded the central B-scans for the presence of cysts, subretinal
fluid, foveal disruption of the external limiting membrane and the photoreceptor layer, and
the presence of disorganization of the retinal inner layers (DRIL).
Statistical analysis
An intraclass correlation coefficient for the number of HF was calculated to assess interrater
agreement. To account for the relationship between both eyes, univariable linear mixed model
analyses were used to assess the difference in CRT, VA and number of HF before and after
treatment, and to evaluate the association between baseline number of HF and (change in)
CRT and VA. To correct for potential confounders, multivariable linear mixed model analyses
were used, applying stepwise backward deletion of non-significant confounders with an influ-
ence of<10% on the estimate of HF at baseline. These analyses were conducted using SPSS
version 22 (SPSS, Chicago, IL, USA). Mixed effect logistic regression analysis was used to
assess associations between baseline number and change of HF with adequate or insufficient
treatment response, expressed as an odds ratio (OR) with 95% confidence interval (CI). These
analyses were performed in SAS Statistical Analysis Software 9.2 (SAS Institute, Cary, NC,
USA). P-values <0.05 were considered statistically significant.
Results
Fifty-four eyes of 41 subjects were evaluated over the course of 3 months of treatment with
bevacizumab. Patient characteristics at baseline are described in Table 1. Mean CRT at baseline
Table 1. Baseline characteristics.
Variable




Age, mean (SD), years 67 (12)
Duration DME per eye, median (IQR), months 8 (2–21)




Presence of cysts per eye, n. (%) 51 (94%)
Presence of subretinal fluid per eye, n (%) 13 (24%)
Foveal disruption of ELM per eye, n (%) 20 (37%)
Foveal disruption of PR layer per eye, n (%) 21 (39%)
n = number; SD = standard deviation, DM = diabetes mellitus; DME = diabetic macular edema; IQR = interquartile
range; DR = diabetic retinopathy; ELM = external limiting membrane; PR = photoreceptor
https://doi.org/10.1371/journal.pone.0206482.t001
HF on OCT and treatment outcome for anti-VEGF in DME
PLOS ONE | https://doi.org/10.1371/journal.pone.0206482 October 31, 2018 4 / 11
was 482 ± 128 μm, and decreased significantly after treatment with bevacizumab to
419 ± 127 μm (p<0.001, Fig 2A). LogMAR VA was 0.54 ± 0.36 (Snellen 20/69) at baseline and
improved to 0.48 ± 0.35 (Snellen 20/60) at the 3 month visit, although this difference did not
reach statistical significance (p = 0.168, Fig 2B). For HF measurements, the intraclass correla-
tion coefficient was 0.85 [0.79–0.89]. Mean number of HF at baseline was 14.8 ± 9.7, and
decreased to 10.7 ± 6.5 (p = 0.002, Fig 2C).
HF were scattered throughout all retinal layers. The mean number of HF in the inner retinal
layers at baseline was 10.4 ± 7.3 versus 7.9 ± 5.0 after treatment (p = 0.010, Fig 2C). In the
outer layers the mean number of HF at baseline was 4.5 ± 4.9 compared to 2.8 ± 3.0 after treat-
ment (p = 0.013, Fig 2C). The percentage of HF with a reflectivity higher than the RPE was
higher in the outer retinal layers (64% at baseline and 68% at 3 months) than in the inner reti-
nal layers (36% at baseline and 25% at 3 months).
The number of HF at baseline was independently associated with a decrease in CRT after 3
months (p = 0.006, Table 2). An estimate of -2.61 was found for this association, implicating
that for every HF counted at baseline, CRT declines with 2.61 μm after treatment. There was
no relation between the number of HF at baseline and baseline CRT (Table 2). When we inves-
tigated the relationship between HF number at baseline and VA outcome measures, we found
that baseline VA was 0.008 points worse for every counted HF (p = 0.047). No effect of baseline
number of HF and change in VA after 3 months was found (Table 2).
Next, we stratified the cohort into two groups with either adequate or insufficient treatment
response. A total of 30 eyes (56%) showed a CRT decrease of�10%, while 16 eyes (30%)
showed an improvement in VA of�0.1 logMAR. Subsequently, 13 eyes (24%) met both CRT
Fig 2. Differences between before and after treatment with anti-VEGF. Mean changes in central retinal thickness
(A), visual acuity (B) and number of hyperreflective foci (C) at baseline and after 3 injections with anti-VEGF. The bars
represent mean ± 95% confidence interval. �P<0.05.
https://doi.org/10.1371/journal.pone.0206482.g002
Table 2. Linear mixed model analysis of the effect of baseline number of HF on baseline values of VA and CRT, and VA and CRT changes.
Univariable Multivariable
Estimate 95% CI P Estimate 95% CI P
CRT baseline, μm -1.89 -5.71–1.94 0.325 -3.54 [-7.44–0.366] 0.074
CRT change, μm -2.47 -4.64 –-0.31 0.026� -2.61 [-4.42–0.79] 0.006�
VA baseline, logMAR 0.013 0.004–0.023 0.008� 0.008 [0.001–0.016] 0.047�
VA change, logMAR -0.002 -0.009–0.004 0.473 -0.002 [-0.006–0.009] 0.661
Multivariable analyses were corrected for gender, age, duration of DME, DR stage, presence of cysts, presence of subretinal fluid, disruption of the external limiting
membrane, disruption of the photoreceptor layer and the presence of disorganization of the retinal inner layers. Analyses of CRT and VA changes were also corrected
for both CRT baseline and VA baseline. Analysis of CRT baseline was also corrected for VA baseline, and analysis of VA baseline was also corrected for CRT baseline.
CI = confidence interval; HF = hyperreflective foci; CRT = central retinal thickness
�P<0.05.
https://doi.org/10.1371/journal.pone.0206482.t002
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and VA criteria for adequate treatment response, classifying 41 eyes (76%) as insufficient
responders. Eyes that were classified as adequate responders presented with higher numbers of
HF at baseline than eyes with insufficient CRT and VA response (21.6±9.5 vs. 12.7±8.8, OR
1.106, 95% CI [1.012–1.210], p = 0.030, Fig 3A–3C). In eyes showing adequate CRT and VA
response, 76% of HF were observed in the inner retinal layers, while this amounted to 66% in
eyes with insufficient response (Fig 3C).
We did not observe a significant difference in HF change between eyes with an adequate
CRT and VA response and eyes with insufficient CRT and VA response (-9.5±7.4 vs. -2.6±8.8,
OR 0.912, 95% CI [0.831–1.001], p = 0.052, Fig 3D–3F). In eyes showing an adequate response,
the decrease in HF was mostly seen in the inner retinal layers, whereas in insufficient respond-
ers this decrease was more prominent in the outer retinal layers (Fig 3F).
Discussion
Higher numbers of HF at baseline were associated with adequate treatment response to anti-
VEGF, in terms of CRT decrease and VA improvement. The relationship between baseline
Fig 3. Difference in number of HF at baseline, and change in HF between eyes with adequate response versus insufficient response. Mean number of HF at
baseline in groups based on insufficient and adequate CRT response (A); insufficient and adequate VA response (B); and insufficient and adequate combined CRT
+ VA response (C). Mean change in number of HF in groups based on insufficient and adequate CRT response (D); insufficient and adequate VA response (E); and
insufficient and adequate combined CRT + VA response (F). The distribution of HF in the inner and outer retinal layers is displayed as a percentage. The values
represent the odds ratio with corresponding 95% confidence interval and p-value. The odds ratio of adequate response is 1.106, which can be interpreted as an
increase, or chance, for adequate response by 10.6% for every HF at baseline; when the number of HF at baseline increases by 10, the chance for adequate response
increases exponentially by 1.10610 = 2.74 or 274%. The bars represent mean ± 95% confidence interval and are based on descriptive statistics. �P<0.05.
https://doi.org/10.1371/journal.pone.0206482.g003
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number of HF and CRT decrease was also apparent in linear mixed model analysis, showing
that the effect was independent from potential confounders. In addition, HF were responsive
to treatment with anti-VEGF, and were more often detected in the inner retinal layers than in
the outer retinal layers. We also observed that a high number of HF at baseline was associated
with poorer VA prior to treatment with anti-VEGF.
The observation that higher numbers of HF at baseline are associated with adequate treat-
ment response could be of importance for clinical practice. For example, when poor response to
anti-VEGF can be predicted based on baseline biomarkers, the decision to start with an alterna-
tive treatment can be made beforehand, thereby preserving visual performance. Ideally, these
findings should be integrated in a prediction model that can reliably predict treatment response,
including all other potential predictive factors, such as patient characteristics, environmental
factors, genotype variables and other imaging biomarkers to be further investigated.
To the best of our knowledge, a relationship between high baseline number of HF and both
adequate morphological and functional treatment outcomes in DME has not been established
before, although it has been studied in other cohorts. An association between higher numbers
of HF and final visual acuity at a mean of 7 months after treatment with bevacizumab in 33
eyes with DME accompanied by serous detachment was reported by Kang et al.[14] Contrarily,
Hwang et al. recently reported fewer numbers of HF to be associated with good CRT response
after 3 months of bevacizumab treatment. The reason for this disparity is unclear, although
there are substantial differences in study design.[15] Hwang et al. studied particles with equal
or higher reflectivity than the RPE, while we used a reflectivity higher than the surrounding tis-
sue for a definition, which in our experience results in a more reliable detection of HF. Fur-
thermore, proliferative diabetic retinopathy is associated with an increased inflammatory
response and exuberant activation of microglia, and we therefore hypothesize that neovascu-
larization could influence the number of HF.[16] For this reason, we excluded patients with
active neovascularization, while DR staging was not reported by Hwang et al. Vujosevic et al.,
who also studied the relationship between baseline HF and treatment response, did not find a
association between baseline number of HF and change in CRT or VA after treatment with
ranibizumab in respectively 20 and 26 eyes with DME, which might be due to small sample
size.[17, 18] Moreover, different criteria for treatment response were used by all study groups:
Hwang et al. chose for a treatment response definition of CRT<300 μm or a reduction by
more than 50 μm, while Kang et al. and Vujosevic et al. defined treatment outcome by the con-
tinuous variables VA improvement and CRT reduction, respectively.[14, 15, 17, 18] We chose
a definition of CRT decrease of>10% and a VA improvement of>0.1 logMAR, as proposed
by the Diabetic Retinopathy Clinical Research Network, as a CRT reduction expressed as a
percentage accounts for differences in baseline CRT, and the combination with VA improve-
ment provides valuable information on visual function.[4, 5]
The association between higher baseline number of HF and poorer baseline VA is in line
with previous studies,[11, 19] and could be a relevant observation for clinical practice. Often,
vision loss is not the first manifestation of DME. Therefore, large-scaled screening programs
are set up for patients with DM to detect early changes related to leakage of fluid into the ret-
ina, such as microaneurysms and hard exudates.[20] It has been suggested that HF are the
missing link between the breakdown of the inner blood–retina barrier and the osmotic swell-
ing of retinal layers.[8] HF, as an earlier representation of microvascular damage, may be
important in the risk assessment for progression of DME and vision loss.
Various different hypotheses have emerged about the origin of HF that might in fact coex-
ist. HF could be precursors of hard exudates,[6, 8, 9] migrating RPE cells,[10] degenerated
photoreceptor cells,[11, 19] or aggregations of activated immune cells, such as microglia.[12]
Microglia are highly ramified phagocytic cells in the retina and are required for neuronal
HF on OCT and treatment outcome for anti-VEGF in DME
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homeostasis and immune defense. VEGF has been demonstrated to induce microglial activa-
tion,[21] engaging a feedback loop in which immune cells in the retina simultaneously express
and release VEGF.[22] Our work shows that HF are responsive to anti-VEGF and reside pre-
dominantly in the inner retinal layers, which is in accordance with microglial cell behavior.
[16, 23] Moreover, the decrease in HF after 3 months of bevacizumab was most prominent in
the inner retinal layers, which supports the hypothesis that HF in these layers correspond to
activated microglia, and that HF in the outer retinal layers may represent a different entity. It
has also been hypothesized that HF are precursors of hard exudates, given the equal reflectivity
on SD-OCT. Hard exudates are commonly located in the outer plexiform layer, and unlike
microglial cells, they are not subject to rapid regression after only 3 months of treatment,
although these dynamics are unknown for precursors of hard exudates.[12, 24, 25] In the outer
retinal layers, we found that most HF had a reflectivity higher than the RPE, in contrast to the
HF in the inner retinal layers. The unresponsiveness to therapy and the hyperreflective appear-
ance suggests that at least some of the HF in the outer layers are precursors of hard exudates or
migrating RPE cells, as was proposed earlier.[10] Further research is warranted to study the
etiology and clinical value of HF, by means of histological and epidemiological studies.
Overall, there was a significant decrease in CRT, but no significant improvement in VA after
3 injections of bevacizumab in this cohort. Earlier studies demonstrated that treatment out-
comes in real life are often inferior to the results of controlled clinical trials.[26, 27] Moreover,
the follow up duration in this study was relatively short, and it is known from large clinical trials
that VA can improve even after the loading dose of 3 injections before stabilizing.[5] Most large
clinical trials include both patients with type 1 or type 2 diabetes. In our study, we only included
patients with type 2 diabetes, which may explain why these patients are slightly older than in
most clinical trials. However, to the best of our knowledge, there is no evidence from previous
studies that age or type of diabetes are associated with worse treatment outcomes.[28]
The use of a well-designed, detailed grading protocol was one of the major strengths of this
study, evidenced by the good interrater agreement. This protocol enables replication of our
findings and validation in other cohorts. Another strength was the well-defined cohort: we
used strict inclusion criteria to limit the analysis to eyes with a completed loading phase and
follow-up. Sample size and the short duration of follow-up can be considered limitations of
our study, although it has been shown that VA response at 3 months is highly predictive for
long term outcomes of anti-VEGF therapy.[29] Another limitation of this study is the grading
of the central horizontal SD-OCT B-scan only, thus we may not be able to generalize our find-
ings to peripheral parts of the macula. The process of HF grading is labor-intensive, and a
computer assisted approach could facilitate fast and replicable grading. Furthermore, the
development of software-based grading is inevitable when translating HF grading from
research to clinical practice, in order to implement feasible evaluation of HF for the clinician.
In conclusion, our results suggest that in patients with DME, baseline number of HF are
correlated with visual acuity as well as anti-VEGF treatment response in terms of CRT reduc-
tion and VA improvement. Replication of our findings in larger cohorts is needed to assess the
validity of our study. Additionally, the relation between HF and other anti-VEGF agents and
corticosteroids needs to be further explored. This knowledge may contribute to the develop-
ment of proper risk assessment, and therefore enable personalized decision making and pre-
vention of overtreatment.
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